.Sminu Bose, MD will present a poster on ATX-101 for #leiomyosarcoma & dedif #liposarcoma at #ASCO22. Is this clinical trial recruiting? clinicaltrials.gov/ct2/show/NCT05… #sarcoma

Last minute (between packing socks and shirts) selection of #sarcoma abstracts #ASCO22 +rEECur trial Emily Keung, MD Tom Wei-Wu Chen Javier Martin Broto Sminu Bose, MD

Durable responses (ORR 27%) to temozolomide and olaparib in uLMS Markers of response? - WES alterations, HRD score, functional assays? 🔸RAD51 functional assays seems the most promising Sminu Bose, MD #sarcoma #lms #asco22

Congrats Dr. Sam Bose on identifying lack of Rad51 and WES alterations associated with favorable outcome EFS in patients with uterine #leiomyosarcoma #ASCO22 #Sarcoma

This was solid data and discussion- one of the best presentations of the meeting. Congrats to the investigators and Sminu Bose who positively nailed this talk.

Herbert Irving Comprehensive Cancer Center at ASCO AACR #VailWorkshop #MCCR22 - just missing Dawn Hershman! Fantastic week of learning with amazing people

Such a unique experience this past week at the AACR ASCO #MCCR22 #Vail workshop. Met amazing oncologists from around the world, learned about clinical trial design with the best PDG, and got to rep Herbert Irving Comprehensive Cancer Center with some of my favorite people ☺️

Therapeutic advances in leiomyosarcoma Kristine Lacuna; Sminu Bose, Mathew Ingham, Gary Schwartz frontiersin.org/articles/10.33…

So proud of Kristine Lacuna, MD for being awarded an #ASCO23 Young Investigator Award, receiving a Conquer Cancer Merit Award, and presenting posters for not one but TWO clinical trials sponsored by NCI CTEP. What a rockstar 🤩 #sarcoma

And that’s a wrap on my last ASCO as a fellow! Check out our #CD40agonist study in advanced #sarcoma with an exciting signal in #DDLPS (mPFS 10.9mo vs. 4mo historical)👉 ascopubs.org/doi/abs/10.120… Grateful to Conquer Cancer, the ASCO Foundation and quadwfoundation for a #MeritAward! #ASCO2023

Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250) #sarcoma #leiomyosarcoma dlvr.it/SsRRZz

Today marks 1 year since the passing of my program director (and many others) Dr. #MarkHeaney, who was a world expert in #mastcelldisorders, #MPN, and #AML for 30+ years, completely committed to patients, education, and family. Would love to hear stories from others to honor him!